Skip to main content

Celldex Therapeutics, Inc 8-K, filed Nov 5, 2026

Celldex Therapeutics, Inc. (CLDX)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Celldex Therapeutics, Inc filed this 8-K on November 5, 2026.

Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 met primary and key secondary endpoints, supporting barzolvolimab in CSU, with a BLA submission planned for 2027. Celldex Therapeutics reported $650.3 million in cash, cash equivalents and marketable securities, funding planned operations through 2028. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits